Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

BACKGROUND: The immunosuppressive desmoplastic stroma of pancreatic cancer represents a major hurdle to developing an effective immune response. Preclinical studies in pancreatic cancer have demonstrated promising anti-tumor activity with Bruton tyrosine kinase (BTK) inhibition combined with program...

Descripción completa

Detalles Bibliográficos
Autores principales: Overman, Michael, Javle, Milind, Davis, Richard E, Vats, Pankaj, Kumar-Sinha, Chandan, Xiao, Lianchun, Mettu, Niharika B, Parra, Edwin R, Benson, Al B, Lopez, Charles D, Munugalavadla, Veerendra, Patel, Priti, Tao, Lin, Neelapu, Sattva, Maitra, Anirban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057435/
https://www.ncbi.nlm.nih.gov/pubmed/32114502
http://dx.doi.org/10.1136/jitc-2020-000587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057435/
https://www.ncbi.nlm.nih.gov/pubmed/32114502
http://dx.doi.org/10.1136/jitc-2020-000587

Ejemplares similares